Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
Arthritis and Rheumatism
|
August 29, 2013
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
Adrian Ciurea, Almut Scherer, Pascale Exer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2017
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10
Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2018
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial
Silvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, et al.
The Journal of Rheumatology
|
February 17, 2018
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort
Monika Hebeisen, Regula Neuenschwander, Almut Scherer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, et al.
BMC Cancer
|
October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Martin Bigler, Roger von Moos, et al.
The Lancet. Oncology
|
June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Jürg Bernhard, Weixiu Luo, Karin Ribi, et al.
European Urology
|
June 18, 2021
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial
Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
Arthritis and Rheumatism
|
August 29, 2013
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
Adrian Ciurea, Almut Scherer, Pascale Exer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2017
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10
Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2018
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial
Silvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, et al.
The Journal of Rheumatology
|
February 17, 2018
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort
Monika Hebeisen, Regula Neuenschwander, Almut Scherer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, et al.
BMC Cancer
|
October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Martin Bigler, Roger von Moos, et al.
The Lancet. Oncology
|
June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Jürg Bernhard, Weixiu Luo, Karin Ribi, et al.
European Urology
|
June 18, 2021
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial
Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, et al.
Page
of 6